Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + Irinotecan in Advanced Solid Tumors
NCT02611024Phase 2Completed
- Sponsor
- PharmaMar
- Start
- May 2016
- Primary completion
- Jul 2025
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 6
01
Overview
A Phase 2 trial of lurbinectedin in small cell lung cancer (SCLC), soft tissue sarcoma (STS), neuroendocrine tumors (NETs), glioblastoma (GBM), endometrial carcinoma, sponsored by PharmaMar. Started May 2016; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)soft tissue sarcoma (STS)neuroendocrine tumors (NETs)glioblastoma (GBM)endometrial carcinoma
Beyond the preview
Go deeper on NCT02611024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611024.